Sulbactam-durlobactam for the treatment of Acinetobacter baumannii-calcoaceticus complex.

Autor:	Covvey JR; Division of Pharmaceutical, Administrative and Social Sciences, Duquesne University School of Pharmacy, Pittsburgh, PA, USA., Guarascio AJ; Division of Pharmacy Practice, Duquesne University School of Pharmacy, Pittsburgh, PA, USA.; Department of Pharmacy, Allegheny General Hospital, Pittsburgh, PA, USA.
Jazyk:	angličtina
Zdroj:	Expert review of anti-infective therapy [Expert Rev Anti Infect Ther] 2024 Sep 08, pp. 1-10. Date of Electronic Publication: 2024 Sep 08.
DOI:	10.1080/14787210.2024.2400703
Abstrakt:	Introduction: Infections with Acinetobacter baumannii-calcoaceticus complex (ABC) pose difficulty for clinicians given a limited arsenal of effective antimicrobials. Sulbactam/durlobactam provides a novel treatment option for patients experiencing hospital- or ventilator-acquired pneumonia with susceptible strains. Areas Covered: This review provides a comprehensive discussion of sulbactam/durlobactam, including basic characteristics, in vitro activity, and clinical trial data supporting its use for the treatment of ABC. Manufacturer's data, published literature to date, and conference data are utilized in this review. Expert Opinion: Sulbactam/durlobactam offers clinicians a new and effective treatment option for resistant ABC infection. Sulbactam, when combined with durlobactam, displays enhanced potency against ABC isolates, which has translated into positive clinical outcomes observed in clinical trials and post-marketing case studies. Although overall treatment indications and clinical experience are limited to date, sulbactam/durlobactam offers a familiar and favorable safety profile in comparison with alternative agents. Factors associated with use of combination antibiotic therapy, availability of commercial drug susceptibility testing, and cost-effectiveness are all currently key considerations for sulbactam/durlobactam use.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu